What is OKYO Pharma?
OKYO Pharma is a biopharmaceutical firm headquartered in London, United Kingdom, dedicated to advancing treatments that enhance the quality of life for patients suffering from ocular conditions. The company's focus on inflammatory eye diseases and ocular pain positions it within a critical segment of the healthcare market, addressing unmet medical needs through innovative therapeutic development.
How much funding has OKYO Pharma raised?
OKYO Pharma has raised a total of $5.8M across 3 funding rounds:
Stock Offering
$2.5M
Other Financing Round
$1.4M
Other Financing Round
$1.9M
Stock Issuance/Offering (2022): $2.5M, investors not publicly disclosed
Other Financing Round (2025): $1.4M, investors not publicly disclosed
Other Financing Round (2025): $1.9M, investors not publicly disclosed
What's next for OKYO Pharma?
The substantial enterprise-level funding indicates a pivotal growth phase for OKYO Pharma. This capital infusion is expected to accelerate the company's research and development pipeline, potentially enabling further clinical trials, expanding its therapeutic portfolio, and solidifying its market presence. The strategic nature of the recent investment suggests strong confidence from financial backers in OKYO Pharma's long-term vision and its capacity to achieve significant milestones in the biopharmaceutical sector.
See full OKYO Pharma company page
